FDA has effectively paused its Commissioner’s National Priority Voucher pilot and appears to have halted new complete response letter postings, according to reports. HHS says work on the program is ongoing.
|Articles|February 27, 2023
WHO Calls for Increased Funding to Aid Yemen’s Health Crisis
Author(s)BioPharm International Editors
WHO is appealing for US $392 million to reach 12.9 million people with essential health assistance in 2023.
Advertisement
On Feb. 26, 2023, the World Health Organization (WHO) appealed for US$392 million to aid in Yemen’s health crisis and reach 12.9 million people with essential health assistance in 2023.
In 2022, international funding pledges enabled WHO and 44 Health Cluster partners to deliver medical equipment, supplies, training, and other support to hospitals and health facilities in Yemen, reaching nearly 7.8 million Yemenis. However, this level of funding fell far short of addressing identified and urgent health needs of nearly 12.6 million people.
“Yemen requires urgent and robust support from international donors and other partners to effectively avert the potential collapse of its health system,” said Adham Abdel Moneim, WHO Representative in Yemen, in a press release. “New funding to the amount of US $392 million is required by Yemen’s health sector to ensure that overstretched health facilities can continue providing even most basic services to 12.9 million of the most vulnerable people.”
Yemen requires continuing support from the international donor community to deliver a minimum health service package that prioritizes access to primary health care services by vulnerable population groups, especially in remote and conflict-affected districts of Yemen where these services are most needed.
Source:
Advertisement
Related to this article
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
3
Ionis Reports 2-Year Donidalorsen (Dawnzera) Data in HAE Prophylaxis
4
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
5